SG11201806595UA - Using cell-free dna fragment size to determine copy number variations - Google Patents
Using cell-free dna fragment size to determine copy number variationsInfo
- Publication number
- SG11201806595UA SG11201806595UA SG11201806595UA SG11201806595UA SG11201806595UA SG 11201806595U A SG11201806595U A SG 11201806595UA SG 11201806595U A SG11201806595U A SG 11201806595UA SG 11201806595U A SG11201806595U A SG 11201806595UA SG 11201806595U A SG11201806595U A SG 11201806595UA
- Authority
- SG
- Singapore
- Prior art keywords
- california
- copy number
- international
- fragments
- illinois
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F18/00—Pattern recognition
- G06F18/20—Analysing
- G06F18/23—Clustering techniques
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F18/00—Pattern recognition
- G06F18/20—Analysing
- G06F18/24—Classification techniques
- G06F18/243—Classification techniques relating to the number of classes
- G06F18/24323—Tree-organised classifiers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/10—Ploidy or copy number detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/10—Sequence alignment; Homology search
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
- G16Z99/00—Subject matter not provided for in other main groups of this subclass
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
- C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
- C12Q2537/16—Assays for determining copy number or wherein the copy number is of special importance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
- C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
- C12Q2537/165—Mathematical modelling, e.g. logarithm, ratio
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Data Mining & Analysis (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Databases & Information Systems (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Primary Health Care (AREA)
- Evolutionary Computation (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Artificial Intelligence (AREA)
- Bioethics (AREA)
- Software Systems (AREA)
- Signal Processing (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization IIIMI41101110101011111 HO 11111011101110011001111101110111110 ill OEN International Bureau ... .1 j (10) International Publication Number (43) International Publication Date ..... ....r;,' WO 2017/136059 Al 10 August 2017(10.08.2017) WIPO I PCT (51) International Patent Classification: JONES, Keith W.; 499 Illinois Street, #210, San Fran- C12Q 1/68 (2006.01) G06F 19/22 (2011.01) cisco, California 94158 (US). CHEN, Gengxin; 499 G06F 19/24 (2011.01) G06F 19/00 (2011.01) Illinois Street, #210, San Francisco, California 94158 G06F 19/18 (2011.01) (US). SKVORTSOV, Dimitri; 499 Illinois Street, #210, San Francisco, California 94158 (US). (21) International Application Number: PCT/US2016/067886 (74) Agents: ZHOU, Feng et al.; WEAVER AUSTIN VIL- LENEUVE & SAMPSON LLP, P. 0. Box 70250, Oak- (22) International Filing Date: land, California 94612-0250 (US). 20 December 2016 (20.12.2016) (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (30) Priority Data: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, 62/290,891 3 February 2016 (03.02.2016) US HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, 15/382,508 16 December 2016 (16.12.2016) US KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (71) Applicant: VERINATA HEALTH, INC. [US/US]; 5200 MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, Illumina Way, San Diego, California 92122 (US). NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (72) Inventors: DUENWALD, Sven; 499 Illinois Street, #210, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, San Francisco, California 94158 (US). COMSTOCK, ZA, ZM, ZW. _ David A.; 499 Illinois Street, #210, San Francisco, Califor- - nia 94158 (US). BARBACIORU, Catalin; 499 Illinois (84) Designated States (unless otherwise indicated, for every _ Street, #210, San Francisco, California 94158 (US). kind of regional protection available): ARIPO (BW, GH, CHUDOVA, Darya I.,; 5931 Taormino Avenue, San Jose, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, California 95123 (US). RAVA, Richard P.; 711 Edge- TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, wood Road, Redwood City, California 94062 (US). TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, = [Continued on next page] (54) Title: USING CELL-FREE DNA FRAGMENT SIZE TO DETERMINE COPY NUMBER VARIATIONS (57) : Disclosed are methods for determining copy number vari- ms 702 I . equencin data = _ 713A 1 7 7139 coverage coverage l short fragm al ents fragments , 713C ation (CNV) known or suspected to be associated with a variety of medical Relative R fre uenc conditions. In some embodiments, methods are provided for determining y of q short copy number variation of fetuses using maternal samples comprising mater- fragments nal and fetal cell free DNA. In some embodiments, methods are provided = — Convert & de multiplex (if I 1 i 71 for determining CNVs known or suspected to be associated with a variety of appficabie) Normalize binned site to total NES value disclosed herein provide methods _ . 1 1 medical conditions. Some embodiments = Alignment • 7 8 Remove global wave, flowcell/batch specific to improve the sensitivity and/or specificity of sequence data analysis by de- riving a fragment size parameter. In some implementations, information 3 71 I i 718 . Tag flitering 8 Binning Correct for GC level from fragments different of sizes are used to evaluate copy number vari- In some implementations, t from ations. one or more -statistics obtained coy- _ ! 7 9 information the interest is used to Compute count. Principle Component Analysis erage of sequence of evaluate copy num- ber In implementations, fetal fraction variations. some one or more estim- 722 = ates are more t-statistics to determine copy number combined with one or Single sample filter 1 variations. _ 72 nEnrichment d tar- etover reference Enrichment of target over reference Enrichment of target ave r reference 729 73r 7 Il One or more Fetal Fractions I statistic t statistic t statistic tz. kin Pass 1: coverage-ell fragments Ploidy Likelihood Pass 2: M coverage - short fragments Pass 3: — -- Figure 2E Il fiaquency of short fra \ .. IN Il © N O WO 2017/136059 Al MIDEDIM01101 DIVIIMMEMIIIM100III11111111111111110111111111111 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, before the expiration of the time limit for amending the LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SI, SK, SM, TR), OAPI GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (BF, BJ, CF, CG, CI, RS, CM, SE, GA, claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) Published: — with international search report (Art. 21(3))
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662290891P | 2016-02-03 | 2016-02-03 | |
US15/382,508 US10095831B2 (en) | 2016-02-03 | 2016-12-16 | Using cell-free DNA fragment size to determine copy number variations |
PCT/US2016/067886 WO2017136059A1 (en) | 2016-02-03 | 2016-12-20 | Using cell-free dna fragment size to determine copy number variations |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201806595UA true SG11201806595UA (en) | 2018-09-27 |
Family
ID=57583028
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201806595UA SG11201806595UA (en) | 2016-02-03 | 2016-12-20 | Using cell-free dna fragment size to determine copy number variations |
Country Status (20)
Country | Link |
---|---|
US (3) | US10095831B2 (en) |
EP (2) | EP3517626B1 (en) |
KR (2) | KR102184868B1 (en) |
CN (2) | CN113096726B (en) |
AR (1) | AR107192A1 (en) |
AU (2) | AU2016391100B2 (en) |
BR (1) | BR112018015913B1 (en) |
CA (1) | CA3013572C (en) |
CY (1) | CY1121741T1 (en) |
DK (1) | DK3202915T3 (en) |
EA (2) | EA035148B1 (en) |
IL (2) | IL260938B (en) |
MA (2) | MA52131A (en) |
NZ (1) | NZ745637A (en) |
SA (1) | SA518392138B1 (en) |
SG (1) | SG11201806595UA (en) |
TW (2) | TWI708848B (en) |
UA (1) | UA126898C2 (en) |
WO (1) | WO2017136059A1 (en) |
ZA (1) | ZA201805753B (en) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014093330A1 (en) | 2012-12-10 | 2014-06-19 | Clearfork Bioscience, Inc. | Methods for targeted genomic analysis |
WO2015061359A1 (en) | 2013-10-21 | 2015-04-30 | Verinata Health, Inc. | Method for improving the sensitivity of detection in determining copy number variations |
US10318704B2 (en) | 2014-05-30 | 2019-06-11 | Verinata Health, Inc. | Detecting fetal sub-chromosomal aneuploidies |
CA2970501C (en) | 2014-12-12 | 2020-09-15 | Verinata Health, Inc. | Using cell-free dna fragment size to determine copy number variations |
MX2018005858A (en) | 2015-11-11 | 2019-02-20 | Resolution Bioscience Inc | High efficiency construction of dna libraries. |
US10095831B2 (en) | 2016-02-03 | 2018-10-09 | Verinata Health, Inc. | Using cell-free DNA fragment size to determine copy number variations |
US11514289B1 (en) * | 2016-03-09 | 2022-11-29 | Freenome Holdings, Inc. | Generating machine learning models using genetic data |
WO2018031739A1 (en) * | 2016-08-10 | 2018-02-15 | New York Genome Center, Inc. | Ultra-low coverage genome sequencing and uses thereof |
WO2018039463A1 (en) | 2016-08-25 | 2018-03-01 | Resolution Bioscience, Inc. | Methods for the detection of genomic copy changes in dna samples |
EP3559841A1 (en) | 2016-12-22 | 2019-10-30 | Grail, Inc. | Base coverage normalization and use thereof in detecting copy number variation |
TWI803477B (en) * | 2017-01-25 | 2023-06-01 | 香港中文大學 | Diagnostic applications using nucleic acid fragments |
US11342047B2 (en) | 2017-04-21 | 2022-05-24 | Illumina, Inc. | Using cell-free DNA fragment size to detect tumor-associated variant |
AU2018355575A1 (en) | 2017-10-27 | 2020-05-21 | Juno Diagnostics, Inc. | Devices, systems and methods for ultra-low volume liquid biopsy |
GB201718620D0 (en) * | 2017-11-10 | 2017-12-27 | Premaitha Ltd | Method of detecting a fetal chromosomal abnormality |
KR20210009299A (en) * | 2018-02-27 | 2021-01-26 | 코넬 유니버시티 | Ultra-sensitive detection of circulating tumor DNA through genome-wide integration |
EP3765633A4 (en) * | 2018-03-13 | 2021-12-01 | Grail, Inc. | Method and system for selecting, managing, and analyzing data of high dimensionality |
US20190295684A1 (en) * | 2018-03-22 | 2019-09-26 | The Regents Of The University Of Michigan | Method and apparatus for analysis of chromatin interaction data |
EP3773534A4 (en) * | 2018-03-30 | 2021-12-29 | Juno Diagnostics, Inc. | Deep learning-based methods, devices, and systems for prenatal testing |
JP6974504B2 (en) | 2018-04-02 | 2021-12-01 | イルミナ インコーポレイテッド | Compositions and Methods for Making Controls for Sequence-Based Genetic Testing |
CA3096678A1 (en) * | 2018-04-13 | 2019-10-17 | Grail, Inc. | Multi-assay prediction model for cancer detection |
TW202410055A (en) | 2018-06-01 | 2024-03-01 | 美商格瑞爾有限責任公司 | Convolutional neural network systems and methods for data classification |
US11574706B2 (en) * | 2018-06-28 | 2023-02-07 | 10X Genomics, Inc. | Systems and methods for visualization of single-cell resolution characteristics |
JP6891150B2 (en) * | 2018-08-31 | 2021-06-18 | シスメックス株式会社 | Analysis method, information processing device, gene analysis system, program, recording medium |
US11610150B2 (en) | 2018-10-09 | 2023-03-21 | Ferrum Health, Inc. | Method for computing performance in multiple machine learning classifiers |
US11488716B2 (en) * | 2018-10-09 | 2022-11-01 | Ferrum Health, Inc. | Method for configuring multiple machine learning classifiers |
US11581062B2 (en) | 2018-12-10 | 2023-02-14 | Grail, Llc | Systems and methods for classifying patients with respect to multiple cancer classes |
CA3119980A1 (en) * | 2018-12-20 | 2020-06-25 | Guardant Health, Inc. | Methods, compositions, and systems for improving recovery of nucleic acid molecules |
WO2020127629A1 (en) * | 2018-12-21 | 2020-06-25 | F. Hoffmann-La Roche Ag | Identification of global sequence features in whole genome sequence data from circulating nucelic acid |
KR102287096B1 (en) * | 2019-01-04 | 2021-08-09 | 테라젠지놈케어 주식회사 | Method for determining fetal fraction in maternal sample |
CA3115513A1 (en) * | 2019-06-03 | 2020-12-10 | Illumina, Inc. | Limit of detection based quality control metric |
CN110373477B (en) * | 2019-07-23 | 2021-05-07 | 华中农业大学 | Molecular marker cloned from CNV fragment and related to porcine ear shape character |
CN110570902B (en) * | 2019-08-27 | 2023-05-23 | 深圳百诺精准医疗科技有限公司 | Copy number variation analysis method, system and computer readable storage medium |
EP4035161A1 (en) | 2019-09-23 | 2022-08-03 | Grail, LLC | Systems and methods for diagnosing a disease condition using on-target and off-target sequencing data |
CN115298324A (en) * | 2019-12-18 | 2022-11-04 | 香港中文大学 | Free DNA fragmentation and nucleases |
CN111028890B (en) * | 2019-12-31 | 2020-09-11 | 东莞博奥木华基因科技有限公司 | CNV detection method based on correction between run |
CN111210873B (en) * | 2020-01-14 | 2023-03-28 | 西安交通大学 | Exon sequencing data-based copy number variation detection method and system, terminal and storage medium |
EP4069864A4 (en) * | 2020-02-05 | 2023-01-25 | The Chinese University Of Hong Kong | Molecular analyses using long cell-free fragments in pregnancy |
CN111477275B (en) * | 2020-04-02 | 2020-12-25 | 上海之江生物科技股份有限公司 | Method and device for identifying multi-copy area in microorganism target fragment and application |
CN111411144B (en) * | 2020-04-21 | 2023-12-22 | 深圳华大因源医药科技有限公司 | Plasma free DNA marker for diagnosing blood flow infection pathogen |
CN113593637B (en) * | 2020-04-30 | 2024-05-03 | 深圳市真迈生物科技有限公司 | Sequencing method, analysis method and analysis system thereof, computer-readable storage medium and electronic device |
KR20220074088A (en) * | 2020-11-27 | 2022-06-03 | 주식회사 지씨지놈 | Method for diagnosing and predicting cancer type based on artificial intelligence |
WO2022119812A1 (en) | 2020-12-02 | 2022-06-09 | Illumina Software, Inc. | System and method for detection of genetic alterations |
CN112766428B (en) * | 2021-04-08 | 2021-07-02 | 臻和(北京)生物科技有限公司 | Tumor molecule typing method and device, terminal device and readable storage medium |
CN113270138B (en) * | 2021-04-13 | 2023-09-22 | 杭州博圣医学检验实验室有限公司 | Analysis method for enriching fetal free DNA (deoxyribonucleic acid) for copy number variation based on bioinformatics |
CN113889187B (en) * | 2021-09-24 | 2022-12-06 | 上海仁东医学检验所有限公司 | Single-sample allele copy number variation detection method, probe set and kit |
EP4413156A1 (en) * | 2021-10-08 | 2024-08-14 | Foundation Medicine, Inc. | Methods and systems for automated calling of copy number alterations |
KR20230114952A (en) * | 2022-01-26 | 2023-08-02 | 권창혁 | Cancer diagnosis apparatus and cancer diagnosis method |
WO2023192942A1 (en) * | 2022-03-31 | 2023-10-05 | Illumina, Inc. | Copy number variant calling for lpa kiv-2 repeat |
CN114464269B (en) * | 2022-04-07 | 2022-07-08 | 国家超级计算天津中心 | Virtual medicine generation method and device and computer equipment |
WO2024044749A1 (en) * | 2022-08-26 | 2024-02-29 | Fred Hutchinson Cancer Center | Cell-free dna sequence data analysis techniques for estimating fetal fraction and predicting preeclampsia |
WO2024173756A1 (en) | 2023-02-17 | 2024-08-22 | Illumina, Inc. | Cell-free dna signals as biomarkers of preeclampsia |
CN116597893B (en) * | 2023-06-14 | 2023-12-15 | 北京金匙医学检验实验室有限公司 | Method for predicting drug resistance gene-pathogenic microorganism attribution |
CN117116344B (en) * | 2023-10-25 | 2024-07-19 | 北京大学第三医院(北京大学第三临床医学院) | Detection system and method for single-cell level PMP22 repeated variation |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100216153A1 (en) | 2004-02-27 | 2010-08-26 | Helicos Biosciences Corporation | Methods for detecting fetal nucleic acids and diagnosing fetal abnormalities |
WO2007145612A1 (en) | 2005-06-06 | 2007-12-21 | 454 Life Sciences Corporation | Paired end sequencing |
WO2008045505A2 (en) | 2006-10-10 | 2008-04-17 | Xenomics, Inc. | Compositions, methods and kits for isolating nucleic acids from body fluids using anion exchange media |
US8262900B2 (en) | 2006-12-14 | 2012-09-11 | Life Technologies Corporation | Methods and apparatus for measuring analytes using large scale FET arrays |
EP3770275A1 (en) | 2007-07-23 | 2021-01-27 | The Chinese University of Hong Kong | Determining a fetal aneuploidy |
CN101889074A (en) | 2007-10-04 | 2010-11-17 | 哈尔西恩莫尔丘勒公司 | Sequencing nucleic acid polymers with electron microscopy |
WO2009051842A2 (en) | 2007-10-18 | 2009-04-23 | The Johns Hopkins University | Detection of cancer by measuring genomic copy number and strand length in cell-free dna |
CA2704118A1 (en) | 2007-11-01 | 2009-05-07 | The Hospital For Sick Children | Method of determining risk for cancer |
LT2562268T (en) | 2008-09-20 | 2017-04-25 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuploidy by sequencing |
US8620593B2 (en) | 2009-11-06 | 2013-12-31 | The Chinese University Of Hong Kong | Size-based genomic analysis |
US9323888B2 (en) * | 2010-01-19 | 2016-04-26 | Verinata Health, Inc. | Detecting and classifying copy number variation |
US9260745B2 (en) | 2010-01-19 | 2016-02-16 | Verinata Health, Inc. | Detecting and classifying copy number variation |
EP2526415B1 (en) | 2010-01-19 | 2017-05-03 | Verinata Health, Inc | Partition defined detection methods |
EP2591433A4 (en) | 2010-07-06 | 2017-05-17 | Life Technologies Corporation | Systems and methods to detect copy number variation |
US9029103B2 (en) | 2010-08-27 | 2015-05-12 | Illumina Cambridge Limited | Methods for sequencing polynucleotides |
US8725422B2 (en) * | 2010-10-13 | 2014-05-13 | Complete Genomics, Inc. | Methods for estimating genome-wide copy number variations |
MX349568B (en) | 2010-11-30 | 2017-08-03 | Univ Hong Kong Chinese | Detection of genetic or molecular aberrations associated with cancer. |
US9411937B2 (en) | 2011-04-15 | 2016-08-09 | Verinata Health, Inc. | Detecting and classifying copy number variation |
ES2605372T3 (en) | 2011-05-31 | 2017-03-14 | Berry Genomics Co., Ltd. | A device to detect the number of copies of fetal chromosomes or tumor cell chromosomes |
PL2561103T3 (en) | 2011-06-29 | 2015-02-27 | Bgi Diagnosis Co Ltd | Noninvasive detection of fetal genetic abnormality |
EP2563937A1 (en) | 2011-07-26 | 2013-03-06 | Verinata Health, Inc | Method for determining the presence or absence of different aneuploidies in a sample |
US9367663B2 (en) | 2011-10-06 | 2016-06-14 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
JP6073902B2 (en) | 2011-10-06 | 2017-02-01 | セクエノム, インコーポレイテッド | Methods and processes for non-invasive assessment of genetic variation |
ES2741966T3 (en) | 2011-12-31 | 2020-02-12 | Bgi Genomics Co Ltd | Method to detect a genetic variation |
EP2805280B1 (en) | 2012-01-20 | 2022-10-05 | Sequenom, Inc. | Diagnostic processes that factor experimental conditions |
US9892230B2 (en) | 2012-03-08 | 2018-02-13 | The Chinese University Of Hong Kong | Size-based analysis of fetal or tumor DNA fraction in plasma |
EP3573066B1 (en) | 2012-03-13 | 2023-09-27 | The Chinese University Of Hong Kong | Methods for analyzing massively parallel sequencing data for noninvasive prenatal diagnosis |
CN103374518B (en) * | 2012-04-12 | 2018-03-27 | 维里纳塔健康公司 | Copy the detection and classification of number variation |
US10504613B2 (en) | 2012-12-20 | 2019-12-10 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
US9920361B2 (en) | 2012-05-21 | 2018-03-20 | Sequenom, Inc. | Methods and compositions for analyzing nucleic acid |
US11261494B2 (en) | 2012-06-21 | 2022-03-01 | The Chinese University Of Hong Kong | Method of measuring a fractional concentration of tumor DNA |
EP2875149B1 (en) | 2012-07-20 | 2019-12-04 | Verinata Health, Inc. | Detecting and classifying copy number variation in a cancer genome |
US20140066317A1 (en) * | 2012-09-04 | 2014-03-06 | Guardant Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
WO2014039556A1 (en) * | 2012-09-04 | 2014-03-13 | Guardant Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
EP2900835A4 (en) | 2012-09-27 | 2016-05-11 | Population Diagnotics Inc | Methods and compositions for screening and treating developmental disorders |
CN105408496A (en) | 2013-03-15 | 2016-03-16 | 夸登特健康公司 | Systems and methods to detect rare mutations and copy number variation |
CA2915626A1 (en) * | 2013-06-17 | 2014-12-24 | Verinata Health, Inc. | Method for determining copy number variations in sex chromosomes |
SI3011051T1 (en) | 2013-06-21 | 2019-05-31 | Sequenom, Inc. | Method for non-invasive assessment of genetic variations |
WO2015061359A1 (en) | 2013-10-21 | 2015-04-30 | Verinata Health, Inc. | Method for improving the sensitivity of detection in determining copy number variations |
US10415083B2 (en) | 2013-10-28 | 2019-09-17 | The Translational Genomics Research Institute | Long insert-based whole genome sequencing |
US10318704B2 (en) | 2014-05-30 | 2019-06-11 | Verinata Health, Inc. | Detecting fetal sub-chromosomal aneuploidies |
CA2970501C (en) | 2014-12-12 | 2020-09-15 | Verinata Health, Inc. | Using cell-free dna fragment size to determine copy number variations |
US10364467B2 (en) | 2015-01-13 | 2019-07-30 | The Chinese University Of Hong Kong | Using size and number aberrations in plasma DNA for detecting cancer |
WO2016134452A1 (en) | 2015-02-26 | 2016-09-01 | Titan Medical Inc. | Method and apparatus for providing access for a surgical procedure |
US10095831B2 (en) * | 2016-02-03 | 2018-10-09 | Verinata Health, Inc. | Using cell-free DNA fragment size to determine copy number variations |
US11342047B2 (en) | 2017-04-21 | 2022-05-24 | Illumina, Inc. | Using cell-free DNA fragment size to detect tumor-associated variant |
-
2016
- 2016-12-16 US US15/382,508 patent/US10095831B2/en active Active
- 2016-12-20 EA EA201891580A patent/EA035148B1/en unknown
- 2016-12-20 MA MA052131A patent/MA52131A/en unknown
- 2016-12-20 CA CA3013572A patent/CA3013572C/en active Active
- 2016-12-20 EP EP19161739.8A patent/EP3517626B1/en active Active
- 2016-12-20 WO PCT/US2016/067886 patent/WO2017136059A1/en active Application Filing
- 2016-12-20 EP EP16205580.0A patent/EP3202915B1/en active Active
- 2016-12-20 AU AU2016391100A patent/AU2016391100B2/en active Active
- 2016-12-20 BR BR112018015913A patent/BR112018015913B1/en active IP Right Grant
- 2016-12-20 KR KR1020197034142A patent/KR102184868B1/en active IP Right Grant
- 2016-12-20 DK DK16205580.0T patent/DK3202915T3/en active
- 2016-12-20 UA UAA201809058A patent/UA126898C2/en unknown
- 2016-12-20 MA MA044822A patent/MA44822A/en unknown
- 2016-12-20 EA EA202090277A patent/EA202090277A3/en unknown
- 2016-12-20 KR KR1020187025212A patent/KR102049191B1/en active IP Right Grant
- 2016-12-20 SG SG11201806595UA patent/SG11201806595UA/en unknown
- 2016-12-20 CN CN202110370145.0A patent/CN113096726B/en active Active
- 2016-12-20 NZ NZ745637A patent/NZ745637A/en unknown
- 2016-12-20 CN CN201680084307.1A patent/CN108884491B/en active Active
- 2016-12-20 TW TW108113871A patent/TWI708848B/en active
- 2016-12-20 TW TW105142299A patent/TWI661049B/en active
- 2016-12-23 AR ARP160104015A patent/AR107192A1/en unknown
-
2018
- 2018-08-01 SA SA518392138A patent/SA518392138B1/en unknown
- 2018-08-01 IL IL260938A patent/IL260938B/en active IP Right Grant
- 2018-08-28 ZA ZA2018/05753A patent/ZA201805753B/en unknown
- 2018-08-31 US US16/119,993 patent/US11430541B2/en active Active
-
2019
- 2019-05-17 AU AU2019203491A patent/AU2019203491B2/en active Active
- 2019-06-20 CY CY20191100642T patent/CY1121741T1/en unknown
-
2020
- 2020-02-17 IL IL272710A patent/IL272710B/en active IP Right Grant
-
2022
- 2022-07-22 US US17/871,853 patent/US20230044849A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201806595UA (en) | Using cell-free dna fragment size to determine copy number variations | |
SG11201810003UA (en) | Using programmable dna binding proteins to enhance targeted genome modification | |
SG11201810331YA (en) | Single chain variable fragment cd3 binding proteins | |
SG11201803666WA (en) | Single image detection | |
SG11201805906WA (en) | Diagnostic and prognostic methods for cardiovascular diseases and events | |
SG11201907679TA (en) | Business verification method and apparatus | |
SG11201804190YA (en) | Method and system for blockchain variant using digital signatures | |
SG11201807334SA (en) | Methods, compositions, and devices for information storage | |
SG11201909420QA (en) | Picture-based vehicle loss assessment method and apparatus, and electronic device | |
SG11201900979VA (en) | Network-based automated prediction modeling | |
SG11201909873TA (en) | Dynamic autonomous vehicle servicing and management | |
SG11201806650VA (en) | Systems and methods for providing a personal distributed ledger | |
SG11201811343SA (en) | System and methods for detecting online fraud | |
SG11201903141QA (en) | Business processing method and apparatus | |
SG11201901296TA (en) | Compositions and methods for detecting rare sequence variants | |
SG11201803667RA (en) | Systems and methods for region-adaptive defect detection | |
SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
SG11201902667UA (en) | Methods and systems for chromatography data analysis | |
SG11201407888RA (en) | Method of sequence determination using sequence tags | |
SG11201810924WA (en) | System and method for secondary analysis of nucleotide sequencing data | |
SG11201806284TA (en) | Low pressure separator having an internal divider and uses therefor | |
SG11201906413XA (en) | Exposure apparatus | |
SG11201811333RA (en) | Solid inspection apparatus and method of use | |
SG11201811108YA (en) | Method and system for providing sales information and insights through a conversational interface | |
SG11201807823WA (en) | Bandwith agnostic tone mapping |